Sulfaphenazole: Benchmarking CYP2C9 Inhibition in Drug Metabolism and Vascular Research

Executive Summary: Sulfaphenazole is a potent, competitive inhibitor of human CYP2C9 (Ki = 0.3 ± 0.1 μM), displaying high selectivity versus other cytochrome P450 isoforms (notably, weak inhibition of CYP2C8/CYP2C18 and none for CYP1A1, 1A2, 3A4, 2C19) (Turner et al., 2022). In vivo, Sulfaphenazole restores endothelial-dependent vasodilation, reduces oxidative stress, and increases nitric oxide bioavailability in diabetic mouse models. It is chemically defined as 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)-benzenesulfonamide (MW 314.4, CAS 526-08-9). APExBIO supplies Sulfaphenazole (C4131) as a research-grade reagent, with validated solubility in DMSO (≥13.15 mg/mL) and ethanol (≥9.92 mg/mL, ultrasonic assistance), and stability when stored at -20°C. The compound is not intended for diagnostic or therapeutic use.

Biological Rationale

Cytochrome P450 enzymes (CYPs) are central to the metabolic clearance of xenobiotics and endogenous substrates. CYP2C9, a major hepatic isoform, metabolizes ~15% of all clinically used drugs, including oral anticoagulants (e.g., warfarin), NSAIDs, and oral hypoglycemics (Turner et al., 2022). Variability in CYP2C9 activity underpins significant drug-drug interactions and pharmacogenetic differences in therapeutic outcomes. Inhibiting CYP2C9 offers a controlled strategy to dissect its contribution to drug metabolism, adverse reactions, and vascular function. Sulfaphenazole is an established chemical probe for this purpose, enabling selective modulation of CYP2C9 activity in cellular and animal models.

Mechanism of Action of Sulfaphenazole

Sulfaphenazole acts as a competitive inhibitor, binding directly to the active site of CYP2C9. This binding precludes substrate access and modulates the enzyme's metabolic activity (PQ401 article). The compound exhibits a Ki of 0.3 ± 0.1 μM for CYP2C9, indicating submicromolar potency under standard assay conditions (37°C, pH 7.4, phosphate buffer). Sulfaphenazole demonstrates much weaker affinity for CYP2C8 and CYP2C18 and shows no appreciable inhibition of CYP1A1, CYP1A2, CYP2C19, or CYP3A4 at concentrations up to 100 μM (APExBIO product data). Mechanistically, this selectivity is attributed to key binding interactions within the CYP2C9 active site, documented in crystallographic and mutagenesis studies. By inhibiting CYP2C9, Sulfaphenazole reduces the formation of superoxide radicals, thereby decreasing oxidative stress and preserving nitric oxide (NO) bioavailability—mechanisms implicated in vascular endothelial dysfunction and ischemia-reperfusion injury (Turner et al., 2022).

Evidence & Benchmarks

• Sulfaphenazole (5.13 mg/kg daily, i.p., 8 weeks) restores endothelium-dependent vasodilation in diabetic db/db mice by reducing oxidative stress and increasing NO bioavailability (Turner et al., 2022).
• In apolipoprotein E knockout mice subjected to ischemia–reperfusion-induced skin injury, Sulfaphenazole reduced severity, improved wound closure, and increased tensile strength of injured tissue (Turner et al., 2022).
• Sulfaphenazole rapidly restored tissue perfusion to pre-injury levels, decreased tissue hypoxia, and reduced inflammation and fibrosis in pressure injury models (Turner et al., 2022).
• In rat models of cardiac ischemia–reperfusion injury, Sulfaphenazole reduced infarct size and improved coronary blood flow by attenuating post-ischemic vascular dysfunction (Turner et al., 2022).
• Sulfaphenazole displays no detectable inhibition of CYP1A1, CYP1A2, CYP2C19, or CYP3A4 at concentrations up to 100 μM, validating its selectivity for CYP2C9 (APExBIO).

This article provides comprehensive mechanistic and translational context beyond prior analyses, such as the CY5NHSESTER review, by integrating vascular, pharmacogenetic, and workflow-oriented perspectives specific to Sulfaphenazole's validated applications.

Applications, Limits & Misconceptions

Sulfaphenazole is widely used in:

• Drug metabolism modulation studies in human hepatic microsomes and recombinant enzyme systems.
• Pharmacogenetic analyses to parse CYP2C9-mediated inter-individual drug response variability.
• Vascular endothelial function research, especially in diabetic or ischemic animal models (Turner et al., 2022).
• Adverse drug reaction (ADR) studies, leveraging its specificity to delineate CYP2C9-driven metabolic liabilities.

Compared to the P-450.com review, this article further details Sulfaphenazole's utility in translational vascular models, clarifying best practices for experimental reproducibility.

Common Pitfalls or Misconceptions

• Non-selectivity: Sulfaphenazole is not a broad-spectrum P450 inhibitor; it does not appreciably inhibit CYP1A1, 1A2, 3A4, or 2C19 at conventional concentrations (APExBIO).
• Solubility: The compound is insoluble in water; stock solutions should be freshly prepared in DMSO or ethanol with ultrasonic assistance for optimal solubility.
• Storage: Long-term storage of Sulfaphenazole solutions is not recommended due to stability concerns; store powder at -20°C.
• In vivo extrapolation: Efficacy and selectivity in rodents may not fully predict human metabolic or vascular responses; species-specific differences exist (Turner et al., 2022).
• Intended use: Sulfaphenazole is for research use only and is not approved for diagnostic or therapeutic applications.

This article updates and clarifies the translational scope and technical boundaries compared to the Endothelin-1.com feature by providing a workflow-oriented summary and referencing the APExBIO C4131 formulation.

Workflow Integration & Parameters

• Product Source: Sulfaphenazole (C4131) is commercially available from APExBIO as a research reagent.
• Solubility: Dissolves in DMSO at ≥13.15 mg/mL; in ethanol at ≥9.92 mg/mL with ultrasonic assistance; insoluble in water.
• Storage: Store at -20°C. Avoid freeze-thaw cycles. Prepare fresh solutions before use.
• Assay Concentration: Typical in vitro use: 0.1–10 μM. In vivo, dosing in mice: 5.13 mg/kg/day, intraperitoneally, for 8 weeks (vascular studies).
• Controls: Include vehicle (DMSO/ethanol) controls in all assays.
• Documentation: Reference batch-specific certificate of analysis and ensure compliance with institutional protocols.

Conclusion & Outlook

Sulfaphenazole remains a benchmark competitive CYP2C9 inhibitor for dissecting the enzyme's role in drug metabolism, vascular endothelial function, and pharmacogenetic variability. Its high selectivity and reproducible in vivo efficacy make it indispensable for mechanistic research on cytochrome P450 2C9 and related adverse drug reactions. New translational applications are emerging, particularly in vascular dysfunction and ischemia–reperfusion injury models. Reliable sourcing and workflow integration, as offered by APExBIO’s C4131 kit, are essential for experimental reproducibility and data integrity. For deeper comparative analysis or application-specific guidance, see related resources on nitric-oxide-synthase.com—this article extends their focus by integrating validated vascular and pharmacogenetic endpoints.